Effect of Limaprost in Combination With Transforaminal Epidural Steroid Injection
Lumbar Spinal Stenosis
About this trial
This is an interventional treatment trial for Lumbar Spinal Stenosis
Eligibility Criteria
Inclusion Criteria:
Patients aged 18 to 85 years
Patients with a new or known diagnosis of lumbar spinal stenosis on Magnetic Resonance Imaging (MRI)
Patients scheduled to undergo TFESI due to low back pain or leg pain
Exclusion Criteria:
Refusal of a patient
Coagulopathy
Systemic infection or local infection at the needle injection site
Patients with lumbar instability
Neoplasms in the needle path
Allergy to amide-type local anesthetics
Decreased cognition to the extent that NRS is incomprehensible
Patients with peripheral vascular disease (including peripheral arterial disease)
Patients taking anticoagulant or antiplatelet drugs
Patients with severe cardiovascular disease or liver or kidney disease
Patinets with cerebral infarction
Patinets with a history of gastrointestinal bleeding
Patinets who have had lumbar spine surgery or are expected to receive it within 12 months
Patients who show positive in the straight leg elevation test
Patients who are allergic or sensitive to limaprost (Opalmon®) and placebo or their ingredients
Sites / Locations
- Seoul National University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Patients who received placebo after transforminal epidural steroid injection
Patients who received limaprost (Opalmon®) after transforaminal epidural steroid injection
Patients who took placebo for 12 weeks after TFESI
Patients who took limaprost (Opalmon®) for 12 weeks after TFESI